16
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Long-term Accuracy of Breast Cancer Risk Assessment Combining Classic Risk Factors and Breast Density

      research-article
      , PhD 1 , , , PhD 1 , , PhD 2 , , MPH 2
      JAMA Oncology
      American Medical Association

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          This cohort study reports the long-term accuracy of the Tyler-Cuzick model combined with breast density in assessment of risk for breast cancer among women in a state registry.

          Key Points

          Question

          How accurate is breast cancer risk assessment during more than 10 years of follow-up?

          Findings

          In a cohort study of 132 139 women attending screening from 1996 to 2014, the Tyrer-Cuzick model with mammographic density was well calibrated (2699 cases observed; 2757 cases expected), with no significant loss in calibration to 19 years after assessment. A high-risk group suitable for preventive therapy included 4645 women (3.5%) and 273 cancers (10.1%).

          Meaning

          Accurate risk assessment for breast cancer is needed for risk-adapted screening and prevention strategies; risk assessment combining classic risk factors and mammographic density may be valid for many years after evaluation.

          Abstract

          Importance

          Accurate long-term breast cancer risk assessment for women attending routine screening could help reduce the disease burden and intervention-associated harms by personalizing screening recommendations and preventive interventions.

          Objective

          To report the accuracy of risk assessment for breast cancer during a period of 19 years.

          Design, Setting, and Participants

          This cohort study of the Kaiser Permanente Washington breast imaging registry included women without previous breast cancer, aged 40 to 73 years, who attended screening from January 1, 1996, through December 31, 2013. Follow-up was completed on December 31, 2014, and data were analyzed from March 2, 2016, through November 13, 2017.

          Exposures

          Risk factors from a questionnaire and breast density from the Breast Imaging and Reporting Data System at entry; primary risk was assessed using the Tyrer-Cuzick model.

          Main Outcomes and Measures

          Incidence of invasive breast cancer was estimated with and without breast density. Follow-up began 6 months after the entry mammogram and extended to the earliest diagnosis of invasive breast cancer, censoring at 75 years of age, 2014, diagnosis of ductal carcinoma in situ, death, or health plan disenrollment. Observed divided by expected (O/E) numbers of cancer cases were compared using exact Poisson 95% CIs. Hazard ratios for the top decile of 10-year risk relative to the middle 80% of the study population were estimated. Constancy of relative risk calibration during follow-up was tested using a time-dependent proportional hazards effect.

          Results

          In this cohort study of 132 139 women (median age at entry, 50 years; interquartile range, 44-58 years), 2699 invasive breast cancers were subsequently diagnosed after a median 5.2 years of follow-up (interquartile range, 2.4-11.1 years; maximum follow-up, 19 years; annual incidence rate [IR] per 1000 women, 2.9). Observed number of cancer diagnoses was close to the expected number (O/E for the Tyrer-Cuzick model, 1.02 [95% CI, 0.98-1.06]; O/E for the Tyrer-Cuzick model with density, 0.98 [95% CI, 0.94-1.02]). The Tyrer-Cuzick model estimated 2554 women (1.9%) to be at high risk (10-year risk of ≥8%), of whom 147 subsequently developed invasive breast cancer (O/E, 0.79; 95% CI, 0.67-0.93; IR per 1000 women, 8.7). The Tyrer-Cuzick model with density estimated more women to be at high risk (4645 [3.5%]; 273 cancers [10.1%]; O/E, 0.78; 95% CI, 0.69-0.88; IR per 1000 women, 9.2). The hazard ratio for the highest risk decile compared with the middle 80% was 2.22 (95% CI, 2.02-2.45) for the Tyrer-Cuzick model and 2.55 (95% CI, 2.33-2.80) for the Tyrer-Cuzick model with density. Little evidence was found for a decrease in relative risk calibration throughout follow-up for the Tyrer-Cuzick model (age-adjusted slope, −0.003; 95% CI, −0.018 to 0.012) or the Tyrer-Cuzick model with density (age-adjusted slope, −0.008; 95% CI, −0.020 to 0.004).

          Conclusions and Relevance

          Breast cancer risk assessment combining classic risk factors with mammographic density may provide useful data for 10 years or more and could be used to guide long-term, systematic, risk-adapted screening and prevention strategies.

          Related collections

          Most cited references22

          • Record: found
          • Abstract: found
          • Article: not found

          A breast cancer prediction model incorporating familial and personal risk factors.

          Many factors determine a woman's risk of breast cancer. Some of them are genetic and relate to family history, others are based on personal factors such as reproductive history and medical history. While many papers have concentrated on subsets of these risk factors, no papers have incorporated personal risk factors with a detailed genetic analysis. There is a need to combine these factors to provide a better overall determinant of risk. The discovery of the BRCA1 and BRCA2 genes has explained some of the genetic determinants of breast cancer risk, but these genes alone do not explain all of the familial aggregation of breast cancer. We have developed a model incorporating the BRCA genes, a low penetrance gene and personal risk factors. For an individual woman her family history is used in conjuction with Bayes theorem to iteratively produce the likelihood of her carrying any genes predisposing to breast cancer, which in turn affects her likelihood of developing breast cancer. This risk was further refined based on the woman's personal history. The model has been incorporated into a computer program that gives a personalised risk estimate. Copyright 2004 John Wiley & Sons, Ltd.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Projecting Individualized Probabilities of Developing Breast Cancer for White Females Who Are Being Examined Annually

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Projecting individualized probabilities of developing breast cancer for white females who are being examined annually.

              To assist in medical counseling, we present a method to estimate the chance that a woman with given age and risk factors will develop breast cancer over a specified interval. The risk factors used were age at menarche, age at first live birth, number of previous biopsies, and number of first-degree relatives with breast cancer. A model of relative risks for various combinations of these factors was developed from case-control data from the Breast Cancer Detection Demonstration Project (BCDDP). The model allowed for the fact that relative risks associated with previous breast biopsies were smaller for women aged 50 or more than for younger women. Thus, the proportional hazards models for those under age 50 and for those of age 50 or more. The baseline age-specific hazard rate, which is the rate for a patient without identified risk factors, is computed as the product of the observed age-specific composite hazard rate times the quantity 1 minus the attributable risk. We calculated individualized breast cancer probabilities from information on relative risks and the baseline hazard rate. These calculations take competing risks and the interval of risk into account. Our data were derived from women who participated in the BCDDP and who tended to return for periodic examinations. For this reason, the risk projections given are probably most reliable for counseling women who plan to be examined about once a year.
                Bookmark

                Author and article information

                Journal
                JAMA Oncol
                JAMA Oncol
                JAMA Oncol
                JAMA Oncology
                American Medical Association
                2374-2437
                2374-2445
                5 April 2018
                September 2018
                5 April 2018
                : 4
                : 9
                : e180174
                Affiliations
                [1 ]Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, England
                [2 ]Kaiser Permanente Washington Health Research Institute, Seattle, Washington
                Author notes
                Article Information
                Accepted for Publication: January 16, 2018.
                Published Online: April 5, 2018. doi:10.1001/jamaoncol.2018.0174
                Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2018 Brentnall AR et al. JAMA Oncology.
                Corresponding Author: Adam R. Brentnall, PhD, Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University of London, Charterhouse Square, London, EC1M 6BQ, England ( a.brentnall@ 123456qmul.ac.uk ).
                Author Contributions: Dr Brentnall had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
                Study concept and design: Brentnall, Cuzick, Buist.
                Acquisition, analysis, or interpretation of data: All authors.
                Drafting of the manuscript: Brentnall.
                Critical revision of the manuscript for important intellectual content: Cuzick, Buist, Bowles.
                Statistical analysis: Brentnall, Cuzick.
                Obtained funding: Buist, Bowles.
                Administrative, technical, or material support: Buist, Bowles.
                Study supervision: Cuzick.
                Conflict of Interest Disclosures: Drs Cuzick and Brentnall report receiving royalty payments through Cancer Research UK for commercial use of the Tyrer-Cuzick algorithm. No other disclosures were reported.
                Funding/Support: This study was supported by grant C569/A16891 from Cancer Research UK; research specialist award R50CA211115 from the National Cancer Institute (NCI) (Ms Bowles); grants HHSN261201100031C and P01CA154292 from the NCI-funded Breast Cancer Surveillance Consortium (Dr Buist); and contracts N01-CN-005230, N01-CN-67009, N01-PC-35142, HHSN261201000029C, and HHSN261201300012I from the Cancer Surveillance System of the Fred Hutchinson Cancer Research Center, funded by the Surveillance, Epidemiology and End Results Program of the NCI with additional support from the Fred Hutchinson Cancer Research Center and the State of Washington.
                Role of the Funder/Sponsor: The sponsors had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
                Additional Contributions: Hongyuan Gao, MS, and Ellen O’Meara, PhD, Kaiser Permanenete Washington Health Research Institute, contributed substantially to the acquisition of data. Neither was compensated beyond funding from the research grants listed above.
                Article
                coi180011
                10.1001/jamaoncol.2018.0174
                6143016
                29621362
                39389792-9414-474a-80e0-68715e80fe21
                Copyright 2018 Brentnall AR et al. JAMA Oncology.

                This is an open access article distributed under the terms of the CC-BY License.

                History
                : 14 November 2017
                : 9 January 2018
                : 16 January 2018
                Funding
                Funded by: Cancer Research UK
                Funded by: National Cancer Institute (NCI)
                Funded by: Breast Cancer Surveillance Consortium
                Funded by: Cancer Surveillance System of the Fred Hutchinson Cancer Research Center
                Categories
                Research
                Research
                Original Investigation
                Online First
                Online Only

                Comments

                Comment on this article